Nutritional management of inflammatory bowel disease;Tratamiento nutricional en la enfermedad inflamatoria intestinal

Nutricion Hospitalaria

Volumn 23, Issue 5, 2008, Pages 418-428

  Perez Tarrago C ^a   Puebla Maestu, A ^a   Mijan De La Torre A ^a,b  

^a UNIVERSITY OF VALLADOLID   (Spain)

^b Hospital Gral   (Spain)

Author keywords

Artificial nutrition; Crohn's disease; Enteral nutrition; Inflammatory bowel disease; Parenteral nutrition; Review; Ulcerative colitis

Indexed keywords

ANTIOXIDANT; CARBOHYDRATE; CORTICOSTEROID; FAT; GLUTAMINE; PREBIOTIC AGENT; PROBIOTIC AGENT; PROTEIN; TRACE ELEMENT; TRANSFORMING GROWTH FACTOR BETA2;

CAUSAL ATTRIBUTION; CROHN DISEASE; DIET THERAPY; ENTERIC FEEDING; ENTERITIS; HIGH FIBER DIET; HUMAN; MALNUTRITION; NUTRITION; NUTRITIONAL DEFICIENCY; OSTEOPOROSIS; REVIEW; STEROID THERAPY; TREATMENT INDICATION; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CHILD; CLINICAL TRIALS AS TOPIC; COLITIS, ULCERATIVE; CROHN DISEASE; ENDOSCOPY; ENTERAL NUTRITION; HUMANS; META-ANALYSIS AS TOPIC; MIDDLE AGED; NUTRITIONAL SUPPORT; OSTEOPOROSIS; PARENTERAL NUTRITION; PRACTICE GUIDELINES AS TOPIC; RISK FACTORS;

EID: 55249106907     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Farmer RG, Whelan G, Fazio VW. Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis. Gastroenterology 1985; 88:1818-25.
2. Langholz E, Munkholm P, Davidsen M y cols. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994; 107:3-11.
3. Moum B, Ebkonm A, Vant MH y cols. Inflammatory bowel disease: reevaluation of the diagnosis in a prospective population based study in south eastern Norway. Gut 1997; 40:328-332.
4. Van Wijlick EHJ, Lennard-Jones J, Schivananda S, Stockbrugger RW, Russel MGVM for the EC-IBD group. IBD: Diagnostic Changes and clinical features over a four-year period. Results of the European Prospective Study on Inflammatory Bowel Disease. New Orleans LA: Digestive Disease Week; 1998. pp. 16-22.
5. Fiocchi C. Inflammatory Bowel disease: Etiology and Pathogenesis. Gastroenterology 1998; 115:182-205.
6. Oyura Y, Bonen DK, Inohara N y cols. A frameshift mutation in NOD2 associated with to susceptibility to Crohn's disease. Nature 2001; 411:603-606.
7. Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347:417-29.
8. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24(Supl. 170):2-6.
9. Truelove SC, Witts LJ: Cortisona in ulcerative colitis. Final report on a therapeutic trial. BMJ 1995; 2:1041.
10. Van Hees PA, Van Elteren PH, Van Lier HJ y cols. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21:279-286.
11. Mate Jiménez J, Pajares García JM. Epidemiología de la Enfermedad inflamatoria intestinal: distribución geográfica y factores ambientales. Rev Esp Enferm Dig 1994; 86:533-539.
12. Brullet E, Bonfill X, Urrutia G y cols. Estudio epidemiológico de la incidencia de enfermedad inflamatoria intestinal en 4 áreas de España. Med Clin (Barc) 1998; 17:651-6.
13. Roth MP, Petersen GM, McElree C y cols. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology 1989; 97:900-904.
14. Hugot JP: CARD15/NOD2 mutations in Crohn's disease. Ann N Y Acad Sci 2006; 1072:9-18.
15. Harries AD, Baird A, Rhodes J. Non-smoking: a feature of ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284:706.
16. Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1998; 114:1143-1150.
17. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med 1987; 107:513-516.
18. O'Keefe SJ. Nutrition and Gastrointestinal disease. Scand J Gastroenterol Suppl 1996; 220:52-9.
19. ASPEN. Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN 2002; 26(1 Supl.):1SA-138SA.
20. Azcue M, Rashid M, Griffiths A y cols. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997; 41:203.
21. Stokes MA. Crohn's disease and nutrition. Br J Surg 1992; 79:391.
22. Wendland BE, Aghdassi E, Tam C y cols. Lipid peroxidation and plasma antioxidant micronutrientes in Crohn disease. Am J Clin Nutr 2001; 79:259.
23. Seidman E, Leleiko N, Ament M y cols. Nutricional issues in pediatric inflammatory bowel disease. J Pediatric Gastroenterol Nutr 1991; 12:424.
24. Goldsmichd S, Graham M. Trace element deficientes in inflammatory bowel disease. Gastroenterol Clin North Am 1989; 18:579.
25. Geerling BJ, Badart-Smook A, Stockbrugger RW y cols. Comprehensive nutricional status in patients with long-stading Cronh disease currently in remission. Am J Clin Nutr 1998; 67:919.
26. Driscoll RH, Meredith SC, Sitrin M y cols. Vitamin D deficiency and bone disease in patients with Crohn's disease. Gastroenterology 1982; 83:1252-8.
27. Siffledeen JS, Siminiski K, Steinhart H y cols. The frequency of vitamin D deficiency in adults with Crohn's disease. Can J Gastroenterol 2003; 17(8):437.
28. Chowers Y, Sela Holland R y cols. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am J Gastroenterol 2000; 95:3498.
29. Nakano E, Taylor CJ, Chada L y cols. Hyperhomocystinemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2003; 37:586.
30. Heatley RV. Assesing nutricional state in inflammatory bowel disease. Gut 1986; 27 Supl. 1:61.
31. Cronin CC, Shanahan F. Anemia in patients with chronic inflammatory bowel disease. Am J Gastroenterol 2001; 96:2296.
32. Gasche C, Lome, MC, Cavil I y cols. Iron, anaemia, and inflammatory bowel disease. Gut 2004; 53:1190.
33. Duggan P, O'Brien M, Kiely M y cols. Vitamin K status in patients with Crohn's disease: another pathogenetic factor of osteoporosis in Crohn's disease? Gut 2001; 48:473.
34. Levy E, Rizwan Y, Thibault L y cols. Altered lipid profile, lipoprotein composition, and oxidant and antioxidant status in pediatric Crohn disease. Am J Clin Nutr 2000; 71:807.
35. Abu-Qurshin R, Naschitz JE, Zuckermann E y cols. Crohn's disease associated with pellagra and increased excretion of 5-hydroxyindolacetic. Am J Med Sci 1997; 313:111.
36. Galland L. Magnesium and inflammatory bowel disease. Magnessium 1988; 7:78.
37. Ojuawo A, Keith, L. The serum concentrations of zinc, copper and selenium in children with inflammatory bowel disease. Cent Afr J Med 2002; 48:116.
38. Valentine JF, Sninsky CA. Prevention and treatment of osteoporosis in patients with inflammatory bowel disease. Am J Gastroenterol 1999; 94:878-83.
39. Andreassen H, Rungby J, Dahlerup JF y cols. Inflammatory bowel disease and osteoporosis. Scand J Gastroenterol 1997; 32:1247-55.
40. Motley RJ, Crawley EO, Evans C y cols. Increased rate of spinal trabecular bone loss in patients with inflammatory bowel disease. Gut 1988; 29:1332-1336.
41. Robinson RJ, Iqbal SJ, Abrams K y cols. Increased bone resorption in patients with Crohn's disease. Aliment Pharmacol Ther 1998; 12:699-705.
42. Liberman UA, Weiss SL, Broll J y cols. The efffect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995; 333:1437-43.
43. Saag KG, Emkey R, Schintzer TJ y cols. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med 1998; 339:292-299.
44. Lin CL, Moniz C, Chow JW. Treatment with fluoride or biphosphonates prevents bone loss associated with colitis in the rat. Calcif Tissue Int 2000; 67:373-7.
45. Bartram SA, Peaston RT, Rawlings DJ y cols. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment Pharmacol Ther 2003; 18(1112):1121-7.
46. Oliva MM, Lake AM. Nutritional considerations and management of the child with inflammatory bowel disease. Nutrition 1996; 12:151.
47. a edición). Madrid: Ediciones Ergón; 2002. pp. 351-358.
48. Lochs H. To feed or not to feed? Are nutritional supplements worthwhile in active Crohn's disease? Gut 2006; 55:306-307.
49. Lomer M, Harvey R, Evans S y cols. Efficacy and tolerability of a low microparticle diet in a double, blind, randomized, pilot study in Crohn's disease. Eur J Gastroenterol Hepatol 2001; 13:101-106.
50. Gibson PR, Shepherd SJ Personal view: food for thought-western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment Pharmacol Ther 2005; 21(12):1399-409.
51. Zachos M, Tondeur M, Griffiths AM. A metaanalysis of enteral nutrition as primary therapy of active Crohn's disease: does formula composition influence efficacy? Cochrane Database Sust Rev 2001; 3:1-24.
52. Lochs H, Dejong C, Hammargvist F y cols. ESPEN guidelines on enteral nutrition: Gastroenterology. Clinical nutrition 2006; 25:260-274.
53. Griffiths AM, Ohlsson A, Sherman P y cols. Metaanalysis of enteral nutrition as primary treatment of active Crohn's disease. Gastroenterology 1995; 108:1056-67.
54. Fernández Bañares F, Cabré E, Esteve-Comas M y cols. How effective is enteral nutrition in inducing clinical remission in active Crohn's disease? A metaanalysis of the randomized clinical trials. JPEN J Parenter Enteral Nutr 1995; 19:356-64.
55. Teahon K, Smethurst P, Pearson M y cols. The effect of elemental diet on permeability and inflammation in Crohn's disease. Gastroenterology 1991; 101:84-87.
56. Lochs H, Meryn S, Marosi L y cols. Has total bowel rest a beneficial effect in the treatment of Crohn's disease? Clin Nutr 1983; 2:61-4.12.
57. Greenberg GR, Fleming CR, Jeejeebhoy KN y cols. Controlled trial of bowel rest and nutritional support in the management of Crohn's disease. Gut 1988; 29:1309-15.
58. Johnson T, Macdonald S, Hill SM y cols. Treatment of active Crohn's disease in children using partial enteral nutrition with liquid formula: a randomised controlled trial. Gut 2006; 55:356-61.
59. Ortiz Leyba C, Montejo JC, Jiménez FJ, López Martínez J, García de Lorenzo A. Recomendaciones para la valoración nutricional y el soporte nutricional especializado de los pacientes críticos. Nutr Hosp 2005; Supl. 2:1-3.
60. Afzal NA, Davies S, Paintin M y cols. Colonic Crohn's Disease in Children Does Not Respond Well to Treatment with Enteral Nutrition If the Ileum Is Not Envolved. Digestive Diseases and Sciences, Vol. 50, No. 8 (August 2005), pp. 1471-1475.
61. Verma S, Kirkwood B, Brown S y cols. Oral nutritional supplementation is effective in the maintenance of remission in Crohn's disease. Dig Liver Dis 2000; 32:769-74.
62. Barbe L, Carbonnel F, Carrat F y cols. Effets de la nutrition artificielle préopératoire dans les résections intstinales pour maladie de Crohn. Gastroenterl Clin Biol 1996; 20:852-857.
63. McIntyre PB, Powell-Tuck J, Wood SR y cols. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986; 27:481-5.
64. González-Huix F, Fernández-Banares F, Esteve-Comas M y cols. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993; 88:227-32.
65. Stenson WF, Cort D, Rodgers J y cols. Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med 1992; 116:609-14.
66. Hawthorne AB, Daneshmend TK, Hawkey CJ y cols. Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. Gut 1992; 33:922-8.
67. Heuschkel RB, Menache CC, Megerian JT y cols. Enteral nutrition and corticosteroids in the treatment of acute Crohn's disease in children. J Pediatr Gastroenterol Nutr 2000; 31(1):8-15.
68. Working group of the Japanese society for Pediatric gastroenterology, Hepatology and Nutrition. Konno M, Kobayashi A, Tomomasa T y cols. Guidelines for the treatment of Crohn's disease in children. Pediatrics International 2006; 48(3):349-352.
69. Thomas AG; Taylor F, Millar V. Dietary intake and nutricional treatment in childhood Crohn's disease. J Pediatr Gatroenterol Nutr 1993; 17:75-81.
70. Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F y cols. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment Pharmacol Ther 2004; 20:167-172.
71. Ringheanu M, Markowitz J. Inflammatory bowel disease in children. Curr Treat Options Gastroenterol 2002; 5(3):181-196.
72. Beattie RM. Enteral nutrition as primary therapy in childhood Crohn's disease: control of intestinal inflammation and anabolic response. JPEN J Parenter Enteral Nutr 2005; 29(4 Supl.):S151-155.
73. Polk DB, Tañer JA, Kerner JA Jr. Improved growth and disease activity alter intermittent administration of a defined diet in children with Crohn's disease. JPEN J Parenter Enteral Nutr 1992; 16:499-504.
74. Wilschanski M, Sherman P, Pencharz P y cols. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996; 38:543-548.
75. Fell JM, Paintin M, Arnaud-Battandier F y cols. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral and polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000; 14:281-289.
76. Verma S, Brown S, Kirkwood B, Giaffer MH. Polymeric versus elemental diet as primary treatment in active Crohn's disease: a randomized, double-blind trial. Am J Gastroenterol 2000; 95(3):735-9.
77. Borrelli O, Cordischi L, Cirulli M. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006; 4(6):744-53.
78. Ludvigsson JF, Krantz M, Bodin L. Elemental versus polymeric enteral nutrition in paediatric Crohn's disease: a multicentre randomized controlled trial. Acta Paediatr 2004; 93(3):327-35.
79. Gassull Fernández-Bañares F, Cabré E y cols. Fat composition may be a clue to explain the primary therapeutic effect of enteral nutrition in Crohn's disease results of a double blind randomised multicentre European trial: Gut 2002; 51;164-168.
80. Kles KA, Chang EB. Short Chain fatty acids impact on intestinal adaptation, inflammation, carcinoma and failure. Gastroenterol 2006; 130:S100-105.
81. Vernia P, Annese V, Bresci G y cols. Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. European Journal of Clinical Investigation 2003; 33:244-248.
82. Breuer RI, Soergel KH, Lashner BA y cols. Short chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomised, placebo controlled trial. Gut 1997; 40:485-91.
83. Vernia P, Marcheggiano A, Caprilli R y cols. Short-chain fatty acid topical treatment in distal ulcerative colitis. Aliment Pharmacol Ther 1995;9:309-13.
84. syndrome. Surg Clin North Am 1991; 71:625-43.
85. Fernández-Bañares F, Hinojosa J Sánchez-Lombrana JL y cols. Randomised clinical trial of Plantado Ovata seeds as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish group for the study of Crohn's disease and ulcerative colitis. Am J Gastroenterol 1999; 94:427-433.
86. Kanauchi O, Iwagana T, Mitsuyama K. Germinated barley food-stuff feeding. A novel nutraceutical therapeutic strategy for ulcerative colitis. Digestion 2001; 63(Supl. 1):60-67.
87. Welters CF, Heineman E, Thunnissen FB y cols. Effect of dietary inulin supplementation on inflammation of pouch mucosa in patients with an ileal pouch-anal anastomosis. Dis Colon Rectum 2002; 45:621-627.
88. Fell JM. Control of systemic and local inflammation with transforming growth factor beta containing formulas. J Parenter Enteral Nutr 2005; 29(4 Supl.):S126-128.
89. Den Hond E, Hiele M, Peeters M y cols. Effect of long-term oral glutamine supplements on small intestinal permeability in patients with Crohn's disease. J Parenter Enteral Nutr 1999; 23(1):7-11.
90. Ockenga J, Borchert K, Stuber E, Lochs H, Manns MP, Bischoff SC. Glutamine-enriched total parenteral nutrition in patients with inflammatory bowel disease. Eur J Clin Nutr 2005; 59(11):1302-9.
91. Kenneth A, Kudsk MD, Yong W y cols. Glutamine enriched total parenteral nutrition maintains intestinal IL4 and mucosal IgA levels. Journal of parenteral and enteral nutrition 2000; 24:270-275.
92. Akobeng AK, Miller V, Stanton J y cols. Double-blind randomized controlled trial of glutamine enriched polymeric diet in the treatment of active Crohn's disease. J Pediatr Gastroenterol Nutr 2000; 30:78-84.
93. Miralles-Barrachina O, Savoye G, Belmonte-Zalar I y cols. Low levels of gluthatione in endoscopic biopsies of patients with Crohn's colitis: the role of malnutrition. Clin Nutr 1999; 18:313-317.
94. Aghdassi E, Wendland BE, Steinhart AH y cols. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. A randomized controlled trial. Am J Gastroenterol 2003; 98:348-53.
95. Geerling BJ, Badart-Smook A, Van Deursen C y cols. Nutritional supplementation with N-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm Bowel Dis 2000; 6(2):77-84.
96. Seidner DL, Lashner BA, Brzezinski A y cols. An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial. Clin Gastroenterol Hepatol 2005; 3(4):358-69.
97. Karp SM, Koch TR. Micronutrient Supplements in Inflammatory Bowel Disease. Dis Mon 2006; 52:211-220.
98. Gionchetti P, Rizzello F, Venturi A, Campieri M. Probiotics in infective diarrhoea and inflammatory bowel diseases. J Gastroenterol Hepatol 2000; 15:489-493.
99. Gionchetti P, Rizzello F, Venturi A y cols. Oral bacteriotherapy as maintenance treatment in patientswith chronic pouchitis: a double-Blind, placebo-controlled trial. Gastroenterology 2000; 119:305-309.
100. Schultz M, Sartor RB. Probiotics and inflammatory bowel diseases. Am J Gastroenterol 2000; 95(Supl. 1):S19-S21.
101. Malin M, Suomalainen H, Saxelin M y cols. Promotion of IgA immune response in patients with Crohn's disease by oral bacteriotherapy with Lactobacillus GG. Ann Nutr Metab 1996; 40:137-145.
102. Plein K, Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Z Gastroenterol 1993; 31:129-134.
103. Drisko JA, Giles CK, Bischoff BJ. Probiotics in health maintenance and disease prevention. Altern Med Rev 2003; 8:143-155.
104. Malchow HA. Crohn's disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn's disease? J Clin Gastroenterol 1997; 25:653-658.
105. Prantera C, Scribano ML; Falasco G y cols. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51(3):405-9.
106. Venturi A, Gionchetti P, Rizzello F y cols. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13:1103-1108.
107. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126:1620-1633.17.
108. Kruis W. Review article: antibiotics and probiotics in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20 Supl. 4:75-8.
109. Kuisma J, Mentula S, Jarvinen H y cols. Effect of Lactobacillus rhamnosus GG on ileal pouch inflammation and microbial flora. Aliment Pharmacol Ther 2003; 17:509-515.